Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BCR-ABL1 F359C

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

BCR-ABL1 fusion (70)

BCR-ABL1 T315I (32)

BCR-ABL1 E255K (10)

BCR-ABL1 V299L (10)

BCR-ABL1 F317L (8)

BCR-ABL1 Y253H (8)

BCR-ABL1 E255V (6)

BCR-ABL1 G250E (6)

BCR-ABL1 M244V (6)

BCR-ABL1 D276G (5)

BCR-ABL1 F359V (5)

BCR-ABL1 L248V (5)

BCR-ABL1 M351T (5)

BCR-ABL1 E279K (4)

BCR-ABL1 G398R (4)

BCR-ABL1 H396P (4)

BCR-ABL1 H396R (4)

BCR-ABL1 L384M (4)

BCR-ABL1 Q252H (4)

BCR-ABL1 V379I (4)

BCR-ABL1 Y253F (4)

SNX2-ABL1 fusion (4)

BCR-ABL1 F317V (3)

BCR-ABL1 F359I (3)

BCR-ABL1 F486S (3)

BCR-ABL1 mutation (3)

NUP214-ABL1 fusion (3)

BCR-ABL1 A397P (2)

BCR-ABL1 E355G (2)

BCR-ABL1 E459K (2)

BCR-ABL1 F317C (2)

BCR-ABL1 F317I (2)

BCR-ABL1 L387M (2)

BCR-ABL1 T315A (2)

BCR-FGFR1 fusion (2)

ABL1 fusion (1)

BCR exon 13-ABL1 exon 3 fusion (1)

BCR-ABL1 C475V (1)

BCR-ABL1 D363G (1)

BCR-ABL1 D444G (1)

BCR-ABL1 E292V (1)

BCR-ABL1 E355G + BCR-ABL1 Q252R (1)

BCR-ABL1 E450G (1)

BCR-ABL1 E450Q (1)

BCR-ABL1 E453A (1)

BCR-ABL1 E98G (1)

BCR-ABL1 F311I (1)

BCR-ABL1 F311V (1)

BCR-ABL1 F359 (1)

BCR-ABL1 F3llL (1)

BCR-ABL1 G250E + BCR-ABL1 F317L (1)

BCR-ABL1 I403T (1)

BCR-ABL1 I403V (1)

BCR-ABL1 I432T (1)

BCR-ABL1 L248R (1)

BCR-ABL1 L323P (1)

BCR-ABL1 L364I (1)

BCR-ABL1 L387F (1)

BCR-ABL1 M388L (1)

BCR-ABL1 M388L + BCR-ABL1 M244V (1)

BCR-ABL1 N336S (1)

BCR-ABL1 N49S (1)

BCR-ABL1 Q252R (1)

BCR-ABL1 Q255K (1)

BCR-ABL1 Q300R (1)

BCR-ABL1 S417T (1)

BCR-ABL1 S417Y (1)

BCR-ABL1 T315M (1)

BCR-ABL1 V229L (1)

BCR-ABL1 V289A (1)

BCR-ABL1 V289I (1)

BCR-ABL1 fusion negative (1)

Chr t(3;9)(p13;q34) FOXP1/ABL1 (1)

ETV6-ABL1 fusion (1)

FOXP1-ABL1 Fusion (1)

INPP5D-ABL1 fusion (1)

BCR exon 1-PDGFRA exon 13 fusion (1)

BCR-JAK2 fusion (1)

ABL1-RCSD1 fusion (0)

BCR-ABL1 V289I + BCR-ABL1 M388L (0)

BCR-ABL1 V338G (0)

JAK2-ABL1 fusion (0)

BCR-ABL1 fusion (70)

BCR-ABL1 T315I (32)

BCR-ABL1 E255K (10)

BCR-ABL1 V299L (10)

BCR-ABL1 F317L (8)

BCR-ABL1 Y253H (8)

BCR-ABL1 E255V (6)

BCR-ABL1 G250E (6)

BCR-ABL1 M244V (6)

BCR-ABL1 D276G (5)

BCR-ABL1 F359V (5)

BCR-ABL1 L248V (5)

BCR-ABL1 M351T (5)

BCR-ABL1 E279K (4)

BCR-ABL1 G398R (4)

BCR-ABL1 H396P (4)

BCR-ABL1 H396R (4)

BCR-ABL1 L384M (4)

BCR-ABL1 Q252H (4)

BCR-ABL1 V379I (4)

BCR-ABL1 Y253F (4)

SNX2-ABL1 fusion (4)

BCR-ABL1 F317V (3)

BCR-ABL1 F359I (3)

BCR-ABL1 F486S (3)

BCR-ABL1 mutation (3)

NUP214-ABL1 fusion (3)

BCR-ABL1 A397P (2)

BCR-ABL1 E355G (2)

BCR-ABL1 E459K (2)

BCR-ABL1 F317C (2)

BCR-ABL1 F317I (2)

BCR-ABL1 L387M (2)

BCR-ABL1 T315A (2)

BCR-FGFR1 fusion (2)

ABL1 fusion (1)

BCR exon 13-ABL1 exon 3 fusion (1)

BCR-ABL1 C475V (1)

BCR-ABL1 D363G (1)

BCR-ABL1 D444G (1)

BCR-ABL1 E292V (1)

BCR-ABL1 E355G + BCR-ABL1 Q252R (1)

BCR-ABL1 E450G (1)

BCR-ABL1 E450Q (1)

BCR-ABL1 E453A (1)

BCR-ABL1 E98G (1)

BCR-ABL1 F311I (1)

BCR-ABL1 F311V (1)

BCR-ABL1 F359 (1)

BCR-ABL1 F3llL (1)

BCR-ABL1 G250E + BCR-ABL1 F317L (1)

BCR-ABL1 I403T (1)

BCR-ABL1 I403V (1)

BCR-ABL1 I432T (1)

BCR-ABL1 L248R (1)

BCR-ABL1 L323P (1)

BCR-ABL1 L364I (1)

BCR-ABL1 L387F (1)

BCR-ABL1 M388L (1)

BCR-ABL1 M388L + BCR-ABL1 M244V (1)

BCR-ABL1 N336S (1)

BCR-ABL1 N49S (1)

BCR-ABL1 Q252R (1)

BCR-ABL1 Q255K (1)

BCR-ABL1 Q300R (1)

BCR-ABL1 S417T (1)

BCR-ABL1 S417Y (1)

BCR-ABL1 T315M (1)

BCR-ABL1 V229L (1)

BCR-ABL1 V289A (1)

BCR-ABL1 V289I (1)

BCR-ABL1 fusion negative (1)

Chr t(3;9)(p13;q34) FOXP1/ABL1 (1)

ETV6-ABL1 fusion (1)

FOXP1-ABL1 Fusion (1)

INPP5D-ABL1 fusion (1)

BCR exon 1-PDGFRA exon 13 fusion (1)

BCR-JAK2 fusion (1)

ABL1-RCSD1 fusion (0)

BCR-ABL1 V289I + BCR-ABL1 M388L (0)

BCR-ABL1 V338G (0)

JAK2-ABL1 fusion (0)

›

11ms

Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance. (PubMed, Malays J Pathol)

Mutational analysis is recommended to identify patients at risk of disease progression. Therefore, early detection of such mutations may allow timely treatment intervention to prevent or overcome resistance.

11 months ago

Journal

|

ABL1 (ABL proto-oncogene 1)

|

BCR-ABL1 E255K • BCR-ABL1 F317L • BCR-ABL1 Y253H • BCR-ABL1 F359C • ABL1 E255K • BCR-ABL1 E459K • ABL1 F317L • ABL1 F359V • ABL1 Y253H • BCR-ABL1 F359

|

imatinib